Chimeric Technologies, Inc.

Los Angeles, CA 90025

SBIR Award Summary

Total Number of Awards 8
Total Value of Awards $2.01MM
First Award Date 09/01/01
Most Recent Award Date 08/01/09

Key Personnel

Last Name Name Awards Contact
Chintalacharuvu Koteswara R Chintalacharuvu 8

8 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-280
Budget: 08/01/09 - 07/31/11

DESCRIPTION (provided by applicant): Multiple myeloma is an incurable monoclonal proliferative disorder of malignant plasma cells affecting more than 14,000 persons in the U.S.A. per year. Conventional therapies and/or bone marrow transplantation only improve survival time with a median of 30-36 months. The goal of Chimeric Technologies, Inc. is...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-80
Budget: 08/15/08 - 07/31/09

DESCRIPTION (provided by applicant): Multiple myeloma is an incurable monoclonal proliferative disorder of malignant plasma cells affecting more than 14,000 persons in the U.S.A. per year. Conventional therapies and/or bone marrow transplantation only improve survival time with a median of 30-36 months. The goal of Chimeric Technologies, Inc. is...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-06
Budget: 09/28/06 - 02/27/08

DESCRIPTION (provided by applicant): Project Summary/Abstract: When breast-feeding is not possible, cow's milk based formulas are the preferred alternative sources of nutrition. Formula milk fed infants have strikingly more morbidity and mortality with infectious diseases as the major cause. S-IgA, lactoferrin and lysozyme in breast milk are the...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/01/06 - 06/30/08

DESCRIPTION (provided by applicant): Antibodies have become the most important and rapidly expanding class of biotherapeutics. There are 12 FDA approved antibodies for human use and 25% of the drugs currently under development are based on antibodies. While most of the antibodies in use and in clinical trials are for systemic administration, the...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/17/04 - 08/31/05

DESCRIPTION (provided by applicant): Multiple myeloma is an incurable monoclonal proliferative disorder of malignant plasma cells affecting more than 14,000 persons in the U.S.A. per year. It is the second most common hemologic malingnacy and his incidnec coninues to rise, producing significant morbidity in the population. Although convention...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/15/04 - 05/14/06

DESCRIPTION (provided by applicant): Rh blood group phenotyping is required both before blood transfusion and to determine if potential Rh incompatibility exists in pregnant women. Normally the Rh phenotype is established by a hemagglutination test. However, a limiting factor with available reagents is that human IgG anti-Rh is unable to induce ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/15/03 - 05/14/04

DESCRIPTION (provided by applicant): Rh blood group phenotyping is required both before blood transfusion and to determine if potential Rh incompatibility exists in pregnant women. Normally the Rh phenotype is established by a hemagglutination test. However, a limiting factor with available reagents is that human IgG anti-Rh is unable to induce ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/01 - 05/31/02

DESCRIPTION (provided by applicant): Rh blood group phenotyping is required both before blood transfusion and also to determine if potential Rh incompatibility exists in pregnant women. Normally the Rh phenotype is established by a hemagglutination test. However, a limiting factor with availab...